Intellia director receives stock grant and options

Intellia Therapeutics director William J. Chase received new equity awards.

Accepted by SEC EDGAR 06/10/2026 - 07:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Intellia Therapeutics director William J. Chase received new equity awards. On June 9, he was granted 9,200 restricted stock units, each representing the right to receive one share of Intellia common stock upon vesting.

He also received a stock option covering 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholders’ meeting. After the RSU grant, Chase directly holds 143,893 common shares.

Insider Trade Summary

Grant/Award: 22,500 shares

Grant/Award 2 txns

Insider CHASE WILLIAM J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	13,300	$0.00	$0.00
Grant/Award	Common Stock	9,200	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 13,300 contracts (Direct); Common Stock — 143,893 shares (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 13,300 contracts (Direct); Common Stock, 134,693 to 143,893 shares (Direct)

Footnotes (2)

1. F1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
2. F2. This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

Key Figures

RSUs granted: 9,200 units Option shares granted: 13,300 shares Option exercise price: $12.89 per share +2 more

5 metrics

RSUs granted 9,200 units Restricted stock units granted June 9, 2026

Option shares granted 13,300 shares Stock option grant June 9, 2026

Option exercise price $12.89 per share Stock option on Intellia common stock

Shares held after grant 143,893 shares Common stock directly owned after RSU award

Option expiration date June 8, 2036 End of exercise period for granted option

Key Terms

restricted stock units, Stock Option (right to buy), exercise price, vests in full

4 terms

restricted stock units financial

"grant of restricted stock units representing a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (right to buy) financial

"Stock Option (right to buy) with respect to 13,300 shares of Common Stock"

exercise price financial

"conversion or exercise price of 12.8900 per share for the stock option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"vests in full on the earlier to occur of the first anniversary or next annual meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Intellia Therapeutics (NTLA) director William J. Chase receive in this Form 4?

He received equity compensation consisting of restricted stock units and stock options. The grant includes 9,200 RSUs and an option on 13,300 shares, providing additional long-term alignment with Intellia’s common stock performance.

How many restricted stock units were granted to the NTLA director?

William J. Chase was granted 9,200 restricted stock units. Each RSU represents a contingent right to receive one share of Intellia common stock, typically delivered when vesting conditions specified in the award agreement are met.

What are the key terms of the stock options granted to the NTLA director?

He received a stock option for 13,300 shares of Intellia common stock at an exercise price of $12.89 per share. The option vests fully on the earlier of the first anniversary of June 9, 2026, or the next annual stockholders’ meeting.

When do William J. Chase’s new Intellia stock options expire?

The stock options granted to William J. Chase expire on June 8, 2036. This long-dated expiration gives him a multi-year window to decide whether to exercise the options, depending on Intellia’s stock performance and his personal circumstances.

How many Intellia common shares does William J. Chase hold after this Form 4?

Following the RSU grant, William J. Chase directly holds 143,893 shares of Intellia common stock. This figure reflects his reported direct ownership after the June 9, 2026 equity award transactions disclosed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHASE WILLIAM J

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET, SUITE 130

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/09/2026		A		9,200	A	$0	143,893	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$12.89	06/09/2026		A		13,300		(2)	06/08/2036	Common Stock	13,300	$0.00	13,300	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

	James Basta, attorney-in-fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)